AstraZeneca (AZN)

Sector:

Pharma and Biotech

Index:

FTSE 100

10,062.00p
   
  • Change Today:
      93.00p
  • 52 Week High: 13,276.00
  • 52 Week Low: 9,501.00
  • Currency: UK Pounds
  • Shares Issued: 1,550.30m
  • Volume: 4,889,045
  • Market Cap: £155,992m
  • RiskGrade: 123
  • Beta: 0.87

AstraZeneca "excited" by positive results in Tezspire clinical trial

By Benjamin Chiou

Date: Friday 08 Nov 2024

LONDON (ShareCast) - (Sharecast News) - AstraZeneca has announced positive high-level results from a phase III for its Texspire treatment for nasal polyps.
The company said results from the WAYPOINT trial, which evaluated the efficacy and safety of Tezspire (otherwise known as tezepelumab) compared to a placebo in adults with severe chronic rhinosinusitis with nasal polyps, showed a "statistically significant and clinically meaningful reduction in the size of nasal polyps and reduced nasal congestion compared to placebo".

Chronic rhinosinusitis with nasal polyps can lead to obstructions in the nasal passage, resulting in disturbances in smell, taste and sleep as well as pain and fatigue.

"The impressive data from the WAYPOINT trial demonstrate tezepelumab's potential as a new treatment for patients whose lives are disrupted by this debilitating disease," said Joseph Han, the co-primary investigator in the trial.

Sharon Barr, executive vice president of biopharmaceuticals R&D at AstraZeneca, said the company was "excited by the positive results".

"These results reinforce that tezepelumab's first-in-class mode of action, targeting TSLP at the top of the inflammatory cascade, effectively addresses the multiple drivers of epithelial-driven inflammatory diseases."

Email this article to a friend

or share it with one of these popular networks:


Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

 

AstraZeneca Market Data

Currency UK Pounds
Share Price 10,062.00p
Change Today 93.00p
% Change 0.93 %
52 Week High 13,276.00
52 Week Low 9,501.00
Volume 4,889,045
Shares Issued 1,550.30m
Market Cap £155,992m
Beta 0.87
RiskGrade 123

AstraZeneca Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
87.66% below the market average87.66% below the market average87.66% below the market average87.66% below the market average87.66% below the market average
88% below the sector average88% below the sector average88% below the sector average88% below the sector average88% below the sector average
Price Trend
27.11% below the market average27.11% below the market average27.11% below the market average27.11% below the market average27.11% below the market average
34.69% above the sector average34.69% above the sector average34.69% above the sector average34.69% above the sector average34.69% above the sector average
Income
78.05% below the market average78.05% below the market average78.05% below the market average78.05% below the market average78.05% below the market average
42.86% below the sector average42.86% below the sector average42.86% below the sector average42.86% below the sector average42.86% below the sector average
Growth
88.44% above the market average88.44% above the market average88.44% above the market average88.44% above the market average88.44% above the market average
94.12% above the sector average94.12% above the sector average94.12% above the sector average94.12% above the sector average94.12% above the sector average

What The Brokers Say

Strong Buy 9
Buy 15
Neutral 5
Sell 0
Strong Sell 1
Total 30
buy
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

AstraZeneca Dividends

  Latest Previous
  1st Interim 2nd Interim
Ex-Div 08-Aug-24 22-Feb-24
Paid 09-Sep-24 25-Mar-24
Amount 100.00¢ 197.00¢

Trades for 21-Nov-2024

Time Volume / Share Price
14:33 580,525 @ 9,867.00p
16:23 506,887 @ 9,866.30p
14:33 580,525 @ 9,867.00p
16:23 506,887 @ 9,867.00p
16:03 0 @ 10,030.00p

AstraZeneca Key Personnel

Chair Michel Demare

Top of Page